Investment
Features
FeesSafety
Academy
More
Pluang+

Permian Basin Royalty Trust declares $0.0196/unit cash distribution for October 2026, excluding Waddell Ranch proceeds.

Company Fundamentals
18 Sep 2026
PRNewsWire
View Source
Neutral
Permian Basin Royalty Trust declares $0.0196/unit cash distribution for October 2026, excluding Waddell Ranch proceeds.

Permian Basin Royalty Trust announced a cash distribution of $0.019593 per unit payable on October 15, 2026, to holders of record as of September 30, 2026. This distribution excludes proceeds from the Waddell Ranch properties due to excess production costs. The increase from the previous month is mainly due to lower Trust expenses, despite lower oil and gas volumes and oil prices. A proposed business combination with Blackbeard Holdings is pending a unitholder vote, with further details to be provided in upcoming reports and meetings.

Permian Basin Royalty Trust announced its September cash distribution and excess cost position on Waddell Ranch properties. For readers following the Energy sector, here is Pluang's market snapshot as of Sep 18, 2026 19:11 WIB: out of 34 priced Energy-sector US stocks, 4 rose and 27 fell. Notable movers include INDO at USD 2.82 (-2.42%), UEC at USD 10.34 (+2.12%), and TTE at USD 90.05 (-1.68%).

More News

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy Corporation's stock is projected to rise about 8.26% to a price target of $127, down slightly from $133, reflecting confidence despite a recent price dip. The company expects a 4.42% increase in earnings per share to $1.89 and a 3.86% ris...

Analyst Insights
Bullish
1 hour ago
Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
2 hours ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
2 hours ago
Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex, a provider of human capital management solutions, will release its Q1 fiscal 2027 earnings on September 23, 2026. Analysts expect earnings per share (EPS) of $1.32, up from $1.22 last year, and revenue of about $1.63 billion, higher than las...

Company Fundamentals
Bullish
3 hours ago
India's gold demand stays strong despite price swings; ETF inflows and futures trading rise in August.

India's gold demand stays strong despite price swings; ETF inflows and futures trading rise in August.

In August, India's gold market showed resilience with steady jewelry buying and physical investment demand despite volatile gold prices. Domestic gold prices rose 12% in August but pulled back in September amid changing Fed policy expectations. Gold ...

Market News
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App